August 20, 2021 07:40 AM EDTUpdated 10:14 AM
Coronavirus

As­traZeneca says mon­o­clon­al an­ti­body com­bo is 77% ef­fec­tive at pre­vent­ing Covid-19

Nicole DeFeudis

Editor

Af­ter hit­ting just about every pot­hole with its Covid-19 vac­cine roll­out, As­traZeneca has some good news to share for an­oth­er pan­dem­ic-re­lat­ed pro­gram: Its mon­o­clon­al an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times